Scarica l'app Stockscreener
6.08
3.93%
0.23
Dopo l'orario di chiusura:
6.08
Precedente Chiudi:
$5.85
Aprire:
$5.95
Volume 24 ore:
446.75K
Relative Volume:
0.99
Capitalizzazione di mercato:
$236.03M
Reddito:
$5.74M
Utile/perdita netta:
$-166.12M
Rapporto P/E:
-1.5208
EPS:
-3.9978
Flusso di cassa netto:
$-131.64M
1 W Prestazione:
-4.10%
1M Prestazione:
-21.45%
6M Prestazione:
-44.73%
1 anno Prestazione:
-7.03%
Intervallo 1D:
$5.95
$6.23
Intervallo di 1 settimana:
$5.75
$6.55
Portata 52W:
$4.93
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Nome
Entrada Therapeutics Inc
Settore
Industria
Telefono
857-305-1825
Indirizzo
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.08 | 227.10M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-11 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Oppenheimer | Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-01-05 | Iniziato | Oppenheimer | Outperform |
| 2023-04-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
Entrada Therapeutics Inc (TRDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entrada Therapeutics Inc (TRDA) Cash Flow - TradingKey
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entrada Therapeutics Inc (TRDA) Balance Sheet - TradingKey
Entrada Therapeutics Inc (TRDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why (TRDA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Entrada Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Mild Stock UptickBanking Earnings Report - dars.gov.et
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates - MSN
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Entrada Therapeutics (TRDA) Gains 4.6% as Biotech Stock Tests Key Resistance Near $7.47Bullish Sentiment - dars.gov.et
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
Entrada Therapeutics (TRDA) Slips 4.5% as Stock Tests Key Support ZoneInvestment Factor - dars.gov.et
Entrada Therapeutics, Inc.(NasdaqGM: TRDA) dropped from Russell 2000 Defensive Index - marketscreener.com
Understanding Momentum Shifts in (TRDA) - Stock Traders Daily
Price to book forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to sales forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Enterprise value to revenue forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA) - TradingView
TRDA Forecast — Price Target — Prediction for 2027 - TradingView
Entrada Therapeutics (TRDA) Declines Nearly 5% as Stock Tests Key Support at $6.81Earnings Quality Factor - dars.gov.et
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entrada Therapeutics (TRDA) Surges 4.11% as Shares Test Resistance Near $7.44Liquidity Sweep - dars.gov.et
TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Avoiding Lag: Real-Time Signals in (TRDA) Movement - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Institutional Confidence - TradingKey
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97 - Stock Titan
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan
Entrada Therapeutics (TRDA) director receives 19,000-share stock option grant - Stock Titan
Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options - Stock Titan
Entrada Therapeutics (TRDA) Gains Ground: Modest Rally Tests Key Resistance LevelsDay Trade Opportunities - newsline.com
Entrada Therapeutics Stockholders Approve Directors and Equity Plans - The Globe and Mail
[8-K] Entrada Therapeutics, Inc. Reports Material Event - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) - The Globe and Mail
Entrada Therapeutics Inc. (TRDA) Q1 2026 Earnings: Narrower Loss Surprises, but No Revenue Weighs on SharesROIC Trend Report - newsline.com
Entrada Therapeutics (TRDA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Entrada Therapeutics Inc. (TRDA) Faces Selling Pressure as Shares Dip to $6.20Triple Top - dars.gov.et
Discipline and Rules-Based Execution in TRDA Response - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA) - The Globe and Mail
TRDA: Strong safety and early efficacy in DMD trials drive confidence in a growing clinical pipeline - TradingView
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial - Pluang
Entrada gets clearance to escalate dose in DMD trial By Investing.com - Investing.com South Africa
Entrada gets clearance to escalate dose in DMD trial - Investing.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study - The Manila Times
Entrada Therapeutics Inc Azioni (TRDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):